The results of our study showed that LTX-315 plus anti-CTLA-4 antibody yielded a favorable anti-tumor effect for residual tumors, which could help lower the tumor recurrence after iRFA of HCC. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.